Nyxoah (NYXH) has released an update.
Nyxoah has launched its Genio system in England, marking a significant milestone in providing innovative treatment for Obstructive Sleep Apnea (OSA). The first successful implants were conducted at University College London Hospitals, underlining the system’s potential to address unmet needs in OSA therapy. With NHS coverage, Nyxoah aims to expand its collaboration with leading hospitals and enhance access to this groundbreaking therapy.
For further insights into NYXH stock, check out TipRanks’ Stock Analysis page.